ClinicalTrials.gg
CompletedNCT03625141Updated Apr 11, 2024Results posted

A Study Evaluating the Safety and Efficacy of Cobimetinib Plus Atezolizumab in BRAFV600 Wild-type Melanoma With Central Nervous System Metastases and Cobimetinib Plus Atezolizumab and Vemurafenib in BRAFV600 Mutation-positive Melanoma With Central Nervous System Metastases

A Phase 2 interventional study of Cobimetinib and Atezolizumab in Metastatic Melanoma, sponsored by Hoffmann-La Roche. Completed at 22 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-04-11.

Sponsored by Hoffmann-La Roche · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
80
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 27 studies testing cobimetinib in Melanoma — 3 open to participants now, 6 under way, 1 of them phase 3. cobimetinib · Melanoma.

Enrollment
8th of 27
80 · median 45
Started
2018
with 4 others
Phase 2
18 of 27
2 open now
Registered
22nd of 27
by date
Lead sponsor
5 of 27
Hoffmann-La Roche

Among the 27 studies testing cobimetinib in Melanoma, this one is the 8th largest by enrollment, is one of 5 that started in 2018, is one of 18 in phase 2, and was the 22nd registered.

Melanoma

3,373 studies on the registry are indexed under Melanoma; 580 are open to participants now.

Browse Melanoma studies →

Open to participants now

3 of the 27 studies testing cobimetinib in Melanoma are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About cobimetinib

cobimetinib: first FDA approval 2015 (COTELLIC), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 467 Melanoma studies recruiting now, 380 (81%) set no upper age limit and 49 (10%) stop at 75 or younger; 47 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies testing cobimetinib in Melanoma, or all of them as a file.
02

Study summary

This study will evaluate the efficacy and safety of cobimetinib plus atezolizumab in participants with BRAFV600 wild-type melanoma with central nervous system (CNS) metastases and of cobimetinib plus atezolizumab and vemurafenib in BRAFV600 mutation-positive melanoma patients with CNS metastases.

03

Conditions studied

  • Metastatic Melanoma

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Disease-specific inclusion criteria:

  • confirmed melanoma with radiologically confirmed
  • Documented BRAFV600 mutation status of melanoma tumour tissue using a validated genetic test.
  • Measurable brain metastases
  • Prior systemic therapy for melanoma is allowed with exceptions as detailed in the exclusion criteria
  • Prior SRT or surgical therapy of ≤ 10 brain metastases is allowed but prior WBRT is not allowed
  • Adverse effects of all prior systemic or local treatment must have either returned to baseline or become stable and manageable prior to initiation of study treatment.

General inclusion criteria:

  • Age ≥18 years
  • Able to comply with the study protocol, in the investigator's judgment
  • Performance Status ≤ 2
  • of > 3 months
  • Willing and able to complete health and quality of life questionnaires required by the protocol
  • Adequate hematologic and end-organ function
  • Female patients of and male patients with partners of childbearing potential must agree to always use two effective forms of during the course of this study and for at least six months after completion of study therapy.
  • Male patients must agree to refrain from donating sperm for at least six months after the last dose of cobimetinib

Exclusion criteria

Exclusion criteria:

Disease-specific exclusion criteria:

  • Ocular melanoma
  • Uncontrolled tumour-related pain
  • Uncontrolled pleural effusion, pericardial effusion, or ascites requiring repeated drainage more than once every 28 days.
  • Prior WBRT treatment for CNS disease
  • Increasing dose during the seven days prior to initiation of study treatment or current dexamethasone or equivalent dose of > 8 mg/day
  • Prior treatment with a BRAF or MEK inhibitor
  • For patients assigned to Cohort 1 only: prior immunotherapy in the setting is not allowed. Prior immunotherapy is allowed in the setting, provided it is completed ≥ 90 days prior to study treatment initiation.

For patients assigned to Cohort 2 only: prior immunotherapy in either the adjuvant or metastatic setting is not allowed.

  • Major surgical procedure other than for diagnosis within four weeks prior to initiation of study treatment, or anticipation of need for a major surgical procedure during the course of the study
  • Known to biopharmaceutical agents produced in Chinese hamster ovary cells or to any formulation component of cobimetinib or atezolizumab or, for patients assigned to Cohort 2 only, vemurafenib
  • Any anti-cancer therapy, including chemotherapy, hormonal therapy and radiotherapy, within two weeks prior to initiation of study treatment
  • Patients assigned to Cohort 2 only: Concomitant treatment with anticonvulsants other than gabapentin, vigabatrin and levetiracetam
  • Patients assigned to Cohort 2 only: acetaminophen is prohibited within seven days prior to initiation of study treatment unless the patient has an absolute to the to the use of non-steroidal anti-inflammatory drugs (NSAIDs) or aspirin
  • Active (other than melanoma) or a prior malignancy within the past three years

General exclusion criteria:

  • Known risk factors for ocular toxicity
  • History of cardiac dysfunction
  • Inability to swallow medications
  • Malabsorption condition that would alter the absorption of orally administered medications
  • Traumatic injury within two weeks prior to initiation of study treatment
  • Prior allogeneic stem cell or solid organ transplantation
  • Active or history of disease or immune deficiency
  • History of idiopathic pulmonary fibrosis, organizing pneumonia (e.g. bronchiolitis obliterans), drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis on screening chest computed tomography (CT) scan
  • Uncontrolled diabetes or symptomatic hyperglycaemia
  • Any Grade ≥ 3 haemorrhage or bleeding event within 28 days of study treatment initiation
  • History of stroke, reversible ischemic neurological defect, or within six months prior to study treatment initiation
  • Positive (HIV) test at screening
  • virus (HBV) infection (chronic or acute)
  • Active virus (HCV) infection
  • Active tuberculosis
  • History of severe allergic, anaphylactic or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins
  • Severe infection within four weeks prior to initiation of study treatment
  • Signs or symptoms of infection within two weeks prior to initiation of study treatment
  • Any serious medical condition or abnormality in clinical laboratory tests that, in the investigator's judgment, precludes the patient's safe participation in, and completion of, the study
  • Any psychological, familial, sociological, or geographical condition that may hamper compliance with the protocol and follow-up after treatment discontinuation
  • Pregnancy, breastfeeding, or intention of becoming pregnant during the study. Women of must have a negative serum pregnancy test result within seven days prior to initiation of study treatment.
  • Treatment with therapeutic oral or IV antibiotics within two weeks prior to initiation of study treatment
  • Administration of a live, attenuated vaccine within four weeks prior to initiationof study treatment or anticipation of need for such a vaccine during the study
  • Treatment with systemic immunostimulatory agents within 28 days or 5 half-lives of the drug, whichever is shorter, prior to study treatment initiation
  • Treatment with systemic medications within two weeks prior to study treatment initiation
  • Treatment with drug within 28 days or 5 half-lives of the drug, whichever is longer, prior to initiation of study treatment
  • For patients to be assigned to Cohort 2 only: anticipated use of any concomitant medication during or within seven days prior to initiation of study treatment that is known to cause
  • Consumption of foods, supplements, or drugs that are strong or moderate enzyme inducers or inhibitors at least seven days prior to initiation of study treatment.
Terms in these criteria, in plain language(23)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
80 participants (actual)

Study arms

  • Experimental
    Cohort 1- cobimetinib and atezolizumab

    Participants with BRAFV600 wild-type disease will be administered cobimetinib on Days 1-21 of each 28-day cycle; and atezolizumab on Days 1 and 15 of each treatment cycle.

    Drug: Cobimetinib · Drug: Atezolizumab

  • Experimental
    Cohort 2 - cobimetinib, atezolizumab and vemurafenib

    Participants with BRAFV600 mutation-positive disease will be administered cobimetinib, atezolizumab and vemurafenib in 28-day treatment cycles. Treatment includes a 28-day run-in period where participants will receive cobimetinib and vemurafenib only. Upon completion of the 28-day run-in period, atezolizumab will be added to their treatment regimen.

    Drug: Cobimetinib · Drug: Atezolizumab · Drug: Vemurafenib

Interventions

  • 60 mg (three tablets of 20 mg each) orally (PO) once a day (QD) on Days 1-21 of each 28-day cycle.

    Also known as: Cotellic

  • Atezolizumab will be given at a fixed dose of 840 mg by intravenous (IV) infusion on Days 1 and 15 of each 28-day cycle. Only for cohort 2, no dose of atezolizumab will be given during the run-in period (cycle 1).

    Also known as: Tecentriq

  • Participants will receive vemurafenib 960 mg (four 240 mg tablets) orally (PO) twice daily (BID) on days 1-21 of the run-in period (cycle 1); thereafter, they will receive vemurafenib 720 mg dose (three 240 mg tablets) PO BID on days 22-28 of cycle 1 and on days 1-28 of all subsequent cycles.

    Also known as: Zelboraf

06

What researchers measure

Primary outcomes

  1. Intracranial Objective Response Rate (ORR)

    Intracranial ORR is defined as the percentage of participants with either a complete response (CR) or a partial response (PR) in their intracranial disease based on two consecutive assessments \>= 4 weeks apart. Disease status for this endpoint will be determined by an Independent Review Committee (IRC) in accordance with Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) with modified measurability definition for intracranial lesions (\>= 0.5 cm by MRI) and allowing up to five intracranial target lesions. CR is defined as disappearance of all lesions. PR is defined as \>=30% decrease in tumor burden, in the absence of CR. The primary endpoint is analyzed on the BRAFV600 mutation positive (Cohort 2) only as the Sponsor had discontinued enrolment into Cohort 1. Data for Cohort 1 was not collected nor analyzed for this outcome measure.

    Time frame: Baseline up to cut of date (approximately 2.5 years)

Secondary outcomes

  1. Extracranial ORR

    Extracranial ORR, defined as the percentage of participants with either a CR or PR in their extracranial disease based on two consecutive assessments \>=4 weeks apart, as determined by the investigator according to RECIST v1.1.

    Time frame: Baseline up to cut of date (approximately 2.5 years)

  2. Overall ORR

    Overall ORR, defined as the percentage of participants with either a CR or PR in their overall disease (i.e. including intracranial and extracranial disease) based on two consecutive assessments \>= 4 weeks apart, as determined by the investigator according to RECIST v1.1. CR was defined as disappearance of all target and non-target lesions and (if applicable) normalization of tumor marker levels. PR was defined as at least a 30 percent (%) decrease in sum of diameters of all target lesions, taking as reference the baseline sum of diameters, in the absence of CR.

    Time frame: Baseline up to cut of date (approximately 2.5 years)

  3. Progression-Free Survival (PFS)

    Intracranial, extracranial and overall PFS defined as the time from study treatment initiation to the first occurrence of disease progression or death from any cause, whichever occurs first, as determined by the investigator according to RECIST v1.1.

    Time frame: Baseline up to cut of date (approximately 2.5 years)

  4. Duration of Response (DOR)

    Intracranial, extracranial and overall DOR, defined as the time from the first occurrence of a documented objective response based on two consecutive assessments ≥ 4 weeks apart to disease progression or death from any cause (whichever occurs first), as determined by the investigator according to RECIST v1.1. This endpoint is analyzed on the BRAFV600 mutation positive (Cohort 2) only as the Sponsor had discontinued enrolment into Cohort 1. Data for Cohort 1 was not collected nor analyzed for this outcome measure.

    Time frame: Baseline up to cut of date (approximately 2.5 years)

  5. Disease Control Rate (DCR)

    Intracranial, extracranial and overall DCR, defined as the percentage of participants with a CR or PR or stable disease (SD) at 16 weeks from study treatment initiation, as determined by the investigator according to RECIST v1.1. CR was defined as disappearance of all target and non-target lesions and (if applicable) normalization of tumor marker levels. PR was defined as at least a 30 percent (%) decrease in sum of diameters of all target lesions, taking as reference the baseline sum of diameters, in the absence of CR. SD is defined as neither sufficient shrinkage to qualify for CR or PR nor sufficient increase to qualify for disease progression. Disease progression is defined as \>=20% increase in tumor burden. This endpoint is analyzed on the BRAFV600 mutation positive (Cohort 2) only as the Sponsor had discontinued enrolment into Cohort 1. Data for Cohort 1 was not collected nor analyzed for this outcome measure.

    Time frame: At 16 weeks

  6. Overall Survival (OS)

    OS is defined as the time from study treatment initiation to death from any cause.

    Time frame: Baseline up to 4 years, 4 months

  7. Time to Cognitive Symptom Deterioration

    Time from study treatment initiation to cognitive symptom deterioration, defined as a change (\>= 10 points on a 0-100 scale) on selected scales of the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-BN20) (visual disorder, motor dysfunction, communication deficit, headaches, seizures and drowsiness).

    Time frame: Up to 48 months

  8. Time to Symptom and Function Deterioration

    Time from study treatment initiation to symptom and function deterioration defined as a change (\>= 10 points on a 0-100 scale) in fatigue, physical functioning, cognitive functioning, or role functioning as measured by the Fatigue, Physical, Cognitive, Role Functioning scales of the EORTC QLQ-C30.

    Time frame: Up to 48 months

  9. Duration of Stable/Improved Health-related Quality of Life (HRQoL) Scores

    Duration of Stable/Improved HRQoL scores as assessed through use of the two-item Global Health Status (GHS)/HRQoL subscale (Questions 29 and 30) of the EORTC QLQ-C30.

    Time frame: Baseline up to cut of date (approximately 2.5 years)

  10. Percentage of Participants With Adverse Events

    The safety profile of Cobimetinib plus Atezolizumab and Cobimetinib plus Atezolizumab plus Vemurafenib is evaluated in terms of occurrence and severity of AEs. Severity will be determined according to the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0 (NCI CTCAE v4.0)

    Time frame: Baseline up to 4 years, 4 months

07

Results

Posted Feb 8, 2024
Limitations and caveats
The Sponsor decided to discontinue enrollment into Cohort 1, which was communicated in a Dear Investigator Letter dated 9 July 2019.

Participant flow

The study was conducted at 21 centers in 7 countries.

Participant flow — Overall Study
MilestoneCohort 1- Cobimetinib and AtezolizumabCohort 2 - Cobimetinib, Atezolizumab and Vemurafenib
Started1565
Completed00
Not completed1565
Withdrew: Adverse event02
Withdrew: Study terminated by sponsor113
Withdrew: Withdrawal by subject30
Withdrew: Withdrawal of consent01
Withdrew: Death1147
Withdrew: Progressive disease02

Outcome measures

PrimaryIntracranial Objective Response Rate (ORR)

Intracranial ORR is defined as the percentage of participants with either a complete response (CR) or a partial response (PR) in their intracranial disease based on two consecutive assessments \>= 4 weeks apart. Disease status for this endpoint will be determined by an Independent Review Committee (IRC) in accordance with Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) with modified measurability definition for intracranial lesions (\>= 0.5 cm by MRI) and allowing up to five intracranial target lesions. CR is defined as disappearance of all lesions. PR is defined as \>=30% decrease in tumor burden, in the absence of CR. The primary endpoint is analyzed on the BRAFV600 mutation positive (Cohort 2) only as the Sponsor had discontinued enrolment into Cohort 1. Data for Cohort 1 was not collected nor analyzed for this outcome measure.

Time frame:
Baseline up to cut of date (approximately 2.5 years)
Reported as:
Number · Percentage of participants
Intracranial Objective Response Rate (ORR)
Percentage of participantsCohort 2 - Cobimetinib, Atezolizumab and Vemurafenib
Intracranial Objective Response Rate (ORR)46.4 (32.99 to 60.26)
SecondaryExtracranial ORR

Extracranial ORR, defined as the percentage of participants with either a CR or PR in their extracranial disease based on two consecutive assessments \>=4 weeks apart, as determined by the investigator according to RECIST v1.1.

Time frame:
Baseline up to cut of date (approximately 2.5 years)
Reported as:
Number · Percentage of participants
Extracranial ORR
Percentage of participantsCohort 1- Cobimetinib and AtezolizumabCohort 2 - Cobimetinib, Atezolizumab and Vemurafenib
Extracranial ORR20.0 (4.33 to 48.09)56.9 (44.04 to 69.15)
SecondaryOverall ORR

Overall ORR, defined as the percentage of participants with either a CR or PR in their overall disease (i.e. including intracranial and extracranial disease) based on two consecutive assessments \>= 4 weeks apart, as determined by the investigator according to RECIST v1.1. CR was defined as disappearance of all target and non-target lesions and (if applicable) normalization of tumor marker levels. PR was defined as at least a 30 percent (%) decrease in sum of diameters of all target lesions, taking as reference the baseline sum of diameters, in the absence of CR.

Time frame:
Baseline up to cut of date (approximately 2.5 years)
Reported as:
Number · Percentage of participants
Overall ORR
Percentage of participantsCohort 1- Cobimetinib and AtezolizumabCohort 2 - Cobimetinib, Atezolizumab and Vemurafenib
Overall ORR26.7 (7.79 to 55.10)52.3 (39.54 to 64.85)
SecondaryProgression-Free Survival (PFS)

Intracranial, extracranial and overall PFS defined as the time from study treatment initiation to the first occurrence of disease progression or death from any cause, whichever occurs first, as determined by the investigator according to RECIST v1.1.

Time frame:
Baseline up to cut of date (approximately 2.5 years)
Reported as:
Median · Months
Progression-Free Survival (PFS)
MonthsCohort 1- Cobimetinib and AtezolizumabCohort 2 - Cobimetinib, Atezolizumab and Vemurafenib
Intracranial2.17 (1.74 to 7.98)5.78 (5.36 to 7.43)
Extracranial4.21 (1.84 to 12.65)10.68 (7.85 to 13.67)
Overall1.81 (1.71 to 3.71)5.49 (5.13 to 7.43)
SecondaryDuration of Response (DOR)

Intracranial, extracranial and overall DOR, defined as the time from the first occurrence of a documented objective response based on two consecutive assessments ≥ 4 weeks apart to disease progression or death from any cause (whichever occurs first), as determined by the investigator according to RECIST v1.1. This endpoint is analyzed on the BRAFV600 mutation positive (Cohort 2) only as the Sponsor had discontinued enrolment into Cohort 1. Data for Cohort 1 was not collected nor analyzed for this outcome measure.

Time frame:
Baseline up to cut of date (approximately 2.5 years)
Reported as:
Median · Months
Duration of Response (DOR)
MonthsCohort 2 - Cobimetinib, Atezolizumab and Vemurafenib
Intracranial6.7 (5.6 to 9.5)
Extracranial11.6 (9.2 to 13.0)
Overall7.4 (5.5 to 9.5)
SecondaryDisease Control Rate (DCR)

Intracranial, extracranial and overall DCR, defined as the percentage of participants with a CR or PR or stable disease (SD) at 16 weeks from study treatment initiation, as determined by the investigator according to RECIST v1.1. CR was defined as disappearance of all target and non-target lesions and (if applicable) normalization of tumor marker levels. PR was defined as at least a 30 percent (%) decrease in sum of diameters of all target lesions, taking as reference the baseline sum of diameters, in the absence of CR. SD is defined as neither sufficient shrinkage to qualify for CR or PR nor sufficient increase to qualify for disease progression. Disease progression is defined as \>=20% increase in tumor burden. This endpoint is analyzed on the BRAFV600 mutation positive (Cohort 2) only as the Sponsor had discontinued enrolment into Cohort 1. Data for Cohort 1 was not collected nor analyzed for this outcome measure.

Time frame:
At 16 weeks
Reported as:
Number · Percentage of participants
Disease Control Rate (DCR)
Percentage of participantsCohort 2 - Cobimetinib, Atezolizumab and Vemurafenib
Intracranial50.8 (38.07 to 63.40)
Extracranial50.8 (38.07 to 63.40)
Overall50.8 (38.07 to 63.40)
SecondaryOverall Survival (OS)

OS is defined as the time from study treatment initiation to death from any cause.

Time frame:
Baseline up to 4 years, 4 months
Reported as:
Median · Months
Overall Survival (OS)
MonthsCohort 2 - Cobimetinib, Atezolizumab and Vemurafenib
Overall Survival (OS)13.40 (10.68 to 16.92)
SecondaryTime to Cognitive Symptom Deterioration

Time from study treatment initiation to cognitive symptom deterioration, defined as a change (\>= 10 points on a 0-100 scale) on selected scales of the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-BN20) (visual disorder, motor dysfunction, communication deficit, headaches, seizures and drowsiness).

Time frame:
Up to 48 months
Reported as:
Median · Months
Time to Cognitive Symptom Deterioration
MonthsCohort 1- Cobimetinib and AtezolizumabCohort 2 - Cobimetinib, Atezolizumab and Vemurafenib
Visual Disorder3.75 (1.87 to NA)2.99 (1.41 to 8.74)
Motor Dysfunction1.87 (1.08 to 19.84)6.70 (3.94 to 13.90)
Communication Deficit6.44 (2.83 to NA)13.90 (6.54 to 21.13)
HeadachesNA (1.08 to NA)10.84 (5.55 to NA)
Seizures8.31 (8.31 to NA)NA (17.74 to NA)
Drowsiness2.83 (1.08 to NA)7.16 (1.94 to NA)
SecondaryTime to Symptom and Function Deterioration

Time from study treatment initiation to symptom and function deterioration defined as a change (\>= 10 points on a 0-100 scale) in fatigue, physical functioning, cognitive functioning, or role functioning as measured by the Fatigue, Physical, Cognitive, Role Functioning scales of the EORTC QLQ-C30.

Time frame:
Up to 48 months
Reported as:
Median · Months
Time to Symptom and Function Deterioration
MonthsCohort 1- Cobimetinib and AtezolizumabCohort 2 - Cobimetinib, Atezolizumab and Vemurafenib
Physical FunctioningNA (0.99 to NA)11.56 (5.55 to NA)
Cognitive Functioning11.99 (1.91 to NA)8.25 (5.55 to NA)
Role Functioning2.83 (1.35 to 6.47)4.07 (1.61 to 6.47)
Fatigue1.35 (0.95 to NA)1.45 (1.38 to 6.47)
SecondaryDuration of Stable/Improved Health-related Quality of Life (HRQoL) Scores

Duration of Stable/Improved HRQoL scores as assessed through use of the two-item Global Health Status (GHS)/HRQoL subscale (Questions 29 and 30) of the EORTC QLQ-C30.

Time frame:
Baseline up to cut of date (approximately 2.5 years)
Reported as:
Median · Months
Duration of Stable/Improved Health-related Quality of Life (HRQoL) Scores
MonthsCohort 1- Cobimetinib and AtezolizumabCohort 2 - Cobimetinib, Atezolizumab and Vemurafenib
Duration of Stable/Improved Health-related Quality of Life (HRQoL) ScoresNA (15.21 to NA)6.14 (3.68 to 10.32)
SecondaryPercentage of Participants With Adverse Events

The safety profile of Cobimetinib plus Atezolizumab and Cobimetinib plus Atezolizumab plus Vemurafenib is evaluated in terms of occurrence and severity of AEs. Severity will be determined according to the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0 (NCI CTCAE v4.0)

Time frame:
Baseline up to 4 years, 4 months
Reported as:
Count of participants · Participants
Percentage of Participants With Adverse Events
ParticipantsCohort 1- Cobimetinib and AtezolizumabCohort 2 - Cobimetinib, Atezolizumab and VemurafenibCohort 2 - Cobimetinib and Vemurafenib
Occurrence15605
Grade 1110
Grade 23131
Grade 39352
Grade 41100
Grade 5112

Adverse events

Collected over Baseline up to 4 years, 4 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cohort 1- Cobimetinib and Atezolizumab11/15 (73.3%)6/15 (40%)15/15 (100%)
Cohort 2 - Cobimetinib, Atezolizumab and Vemurafenib47/60 (78.3%)21/60 (35%)60/60 (100%)
Cohort 2 - Cobimetinib and Vemurafenib3/5 (60%)5/5 (100%)4/5 (80%)
Most frequent serious events
Showing 10 of 45
Most frequent serious events
EventCohort 1- Cobimetinib and AtezolizumabCohort 2 - Cobimetinib, Atezolizumab and VemurafenibCohort 2 - Cobimetinib and Vemurafenib
Gallbladder ruptureHepatobiliary disorders0/150/601/5
Septic shockInfections and infestations0/150/601/5
Drug reaction with eosinophilia and systemic symptomsSkin and subcutaneous tissue disorders0/150/601/5
RashSkin and subcutaneous tissue disorders0/151/601/5
Rash maculo-papularSkin and subcutaneous tissue disorders0/150/601/5
Cardiac failureCardiac disorders1/150/600/5
Upper gastrointestinal haemorrhageGastrointestinal disorders1/150/600/5
DeathGeneral disorders1/150/600/5
Influenza like illnessGeneral disorders1/150/600/5
Hepatitis toxicHepatobiliary disorders1/150/600/5
Most frequent other events
Showing 10 of 120
Most frequent other events
EventCohort 1- Cobimetinib and AtezolizumabCohort 2 - Cobimetinib, Atezolizumab and VemurafenibCohort 2 - Cobimetinib and Vemurafenib
DiarrhoeaGastrointestinal disorders6/1529/600/5
Blood creatine phosphokinase increasedInvestigations2/1528/600/5
PyrexiaGeneral disorders3/1526/601/5
Lipase increasedInvestigations0/1523/600/5
RashSkin and subcutaneous tissue disorders1/1520/600/5
AstheniaGeneral disorders4/1519/600/5
Amylase increasedInvestigations0/1519/600/5
ArthralgiaMusculoskeletal and connective tissue disorders2/1519/601/5
Dermatitis acneiformSkin and subcutaneous tissue disorders4/1518/600/5
Rash maculo-papularSkin and subcutaneous tissue disorders2/1517/601/5

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Cohort 1- Cobimetinib and AtezolizumabCohort 2 - Cobimetinib, Atezolizumab and VemurafenibTotal
Mean60.9 ± 12.554.4 ± 13.955.6 ± 13.8
Sex: Female, Male
Sex: Female, Male(Participants)Cohort 1- Cobimetinib and AtezolizumabCohort 2 - Cobimetinib, Atezolizumab and VemurafenibTotal
Female92433
Male64147
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Cohort 1- Cobimetinib and AtezolizumabCohort 2 - Cobimetinib, Atezolizumab and VemurafenibTotal
Hispanic or Latino099
Not Hispanic or Latino115061
Unknown or Not Reported4610
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Cohort 1- Cobimetinib and AtezolizumabCohort 2 - Cobimetinib, Atezolizumab and VemurafenibTotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American000
White116172
More than one race000
Unknown or Not Reported448
08

Study locations

22 sites
  • Instituto Nacional de Cancer - INCa; Oncologia
    Rio de Janeiro, RJ 20560-120, Brazil
  • Oncosite - Centro de Pesquisa Clinica Em Oncologia Ltda
    Ijui, RS 98700-000, Brazil
  • Hospital das Clinicas - UFRGS
    Porto Alegre, RS 90035-903, Brazil
  • CHU de Nantes; Cancéro-dermatologie
    Nantes, 44093, France
  • Institut Claudius Regaud; Departement Oncologie Medicale
    Toulouse, 31059, France
  • Institut Gustave Roussy; Dermatologie
    Villejuif, 94805, France
  • Universitätsklinikum "Carl Gustav Carus"; Klinik und Poliklinik fur Dermatologie
    Dresden, 01307, Germany
  • Orszagos Onkologiai Intezet; Borgyogyaszati Osztaly
    Budapest, 1122, Hungary
  • IRCCS Istituto Nazionale Tumori Fondazione Pascale; Oncologia Medica B
    Napoli, Campania 80131, Italy
  • Istituto Dermopatico dell'Immacolata (IDI)-IRCCS; IV Divisione Oncologica e Dermatologia Oncologica
    Roma, Lazio 00167, Italy
  • IRCCS Istituto Nazionale Per La Ricerca Sul Cancro (IST); Oncologia Medica A
    Genova, Liguria 16132, Italy
  • Irccs Istituto Europeo Di Oncologia (IEO); Oncologia Medica
    Milano, Lombardia 20141, Italy
  • Azienda Ospedaliero - Universitaria Pisana U.O. Oncologia Medica 2 Universitaria ? Polo Oncologico
    Pisa, Toscana 56126, Italy
  • IOV - Istituto Oncologico Veneto IRCCS
    Padova, Veneto 35128, Italy
  • Riga East Clinical University Hospital Latvian Oncology Centre
    Riga, LV-1079, Latvia
  • Onkologikoa - Instituto Oncológico de Donostia
    San Sebastian, Guipuzcoa 20014, Spain
  • Hospital Clínic i Provincial; Servicio de Hematología y Oncología
    Barcelona, 08036, Spain
  • Institut Catala d Oncologia Hospital Duran i Reynals
    Barcelona, 08908, Spain
  • Hospital General Universitario Gregorio Marañon; Servicio de Oncologia
    Madrid, 28007, Spain
  • Hospital Universitario Virgen Macarena; Servicio de Oncologia
    Sevilla, 41009, Spain
  • Hospital General Universitario de Valencia; Servicio de oncologia
    Valencia, 46014, Spain
  • Universitätsspital Zürich; USZ Flughafen / H13-7-609
    Zürich, 8091, Switzerland
09

References and documents

Publications

  • Dummer R, Queirolo P, Abajo Guijarro AM, Hu Y, Wang D, de Azevedo SJ, Robert C, Ascierto PA, Chiarion-Sileni V, Pronzato P, Spagnolo F, Mujika Eizmendi K, Liszkay G, de la Cruz Merino L, Tawbi H. Atezolizumab, vemurafenib, and cobimetinib in patients with melanoma with CNS metastases (TRICOTEL): a multicentre, open-label, single-arm, phase 2 study. Lancet Oncol. 2022 Sep;23(9):1145-1155. doi: 10.1016/S1470-2045(22)00452-1. Epub 2022 Aug 5. PubMed 35940183 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2018 to primary completion in Jun 2021, 29 months.

Results were first posted in Feb 2024, 2 years 8 months after primary completion.

Of 106 industry-sponsored phase 2 interventional studies under Melanoma, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 60. This study's 29 months is below that.

Counting every sponsor, half of 384 studies reached it within 53 months; a quarter within 32 and three quarters within 90.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 2, 2018
First posted
Aug 10, 2018
StartActual
Dec 13, 2018
Primary completionActual
Jun 7, 2021
CompletionActual
Apr 13, 2023
Results first posted
Feb 8, 2024
Last update
Apr 11, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 11, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03625141
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Aug 10, 2018
Start date
Dec 13, 2018
Primary completion
Jun 7, 2021
Completion
Apr 13, 2023
Results posted
Feb 8, 2024
Last update
Apr 11, 2024

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Cobimetinib · Atezolizumab

Start the discussion